242 related articles for article (PubMed ID: 24603943)
1. Harnessing the immune system for treatment and detection of tau pathology.
Congdon EE; Krishnaswamy S; Sigurdsson EM
J Alzheimers Dis; 2014; 40 Suppl 1(0):S113-21. PubMed ID: 24603943
[TBL] [Abstract][Full Text] [Related]
2. Tau immunotherapy and imaging.
Sigurdsson EM
Neurodegener Dis; 2014; 13(2-3):103-6. PubMed ID: 24029727
[TBL] [Abstract][Full Text] [Related]
3. Tau Immunotherapy.
Sigurdsson EM
Neurodegener Dis; 2016; 16(1-2):34-8. PubMed ID: 26551002
[TBL] [Abstract][Full Text] [Related]
4. Antibody uptake into neurons occurs primarily via clathrin-dependent Fcγ receptor endocytosis and is a prerequisite for acute tau protein clearance.
Congdon EE; Gu J; Sait HB; Sigurdsson EM
J Biol Chem; 2013 Dec; 288(49):35452-65. PubMed ID: 24163366
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy targeting pathological tau prevents cognitive decline in a new tangle mouse model.
Boutajangout A; Quartermain D; Sigurdsson EM
J Neurosci; 2010 Dec; 30(49):16559-66. PubMed ID: 21147995
[TBL] [Abstract][Full Text] [Related]
6. A walk through tau therapeutic strategies.
Jadhav S; Avila J; Schöll M; Kovacs GG; Kövari E; Skrabana R; Evans LD; Kontsekova E; Malawska B; de Silva R; Buee L; Zilka N
Acta Neuropathol Commun; 2019 Feb; 7(1):22. PubMed ID: 30767766
[TBL] [Abstract][Full Text] [Related]
7. Affinity of Tau antibodies for solubilized pathological Tau species but not their immunogen or insoluble Tau aggregates predicts in vivo and ex vivo efficacy.
Congdon EE; Lin Y; Rajamohamedsait HB; Shamir DB; Krishnaswamy S; Rajamohamedsait WJ; Rasool S; Gonzalez V; Levenga J; Gu J; Hoeffer C; Sigurdsson EM
Mol Neurodegener; 2016 Aug; 11(1):62. PubMed ID: 27578006
[TBL] [Abstract][Full Text] [Related]
8. Amyloid reduction by amyloid-beta vaccination also reduces mouse tau pathology and protects from neuron loss in two mouse models of Alzheimer's disease.
Wilcock DM; Gharkholonarehe N; Van Nostrand WE; Davis J; Vitek MP; Colton CA
J Neurosci; 2009 Jun; 29(25):7957-65. PubMed ID: 19553436
[TBL] [Abstract][Full Text] [Related]
9. Targeting phospho-Ser422 by active Tau Immunotherapy in the THYTau22 mouse model: a suitable therapeutic approach.
Troquier L; Caillierez R; Burnouf S; Fernandez-Gomez FJ; Grosjean ME; Zommer N; Sergeant N; Schraen-Maschke S; Blum D; Buee L
Curr Alzheimer Res; 2012 May; 9(4):397-405. PubMed ID: 22272619
[TBL] [Abstract][Full Text] [Related]
10. Prevention of tau seeding and propagation by immunotherapy with a central tau epitope antibody.
Albert M; Mairet-Coello G; Danis C; Lieger S; Caillierez R; Carrier S; Skrobala E; Landrieu I; Michel A; Schmitt M; Citron M; Downey P; Courade JP; Buée L; Colin M
Brain; 2019 Jun; 142(6):1736-1750. PubMed ID: 31038156
[TBL] [Abstract][Full Text] [Related]
11. Distinct Therapeutic Mechanisms of Tau Antibodies: Promoting Microglial Clearance Versus Blocking Neuronal Uptake.
Funk KE; Mirbaha H; Jiang H; Holtzman DM; Diamond MI
J Biol Chem; 2015 Aug; 290(35):21652-62. PubMed ID: 26126828
[TBL] [Abstract][Full Text] [Related]
12. Two novel Tau antibodies targeting the 396/404 region are primarily taken up by neurons and reduce Tau protein pathology.
Gu J; Congdon EE; Sigurdsson EM
J Biol Chem; 2013 Nov; 288(46):33081-95. PubMed ID: 24089520
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements.
Asuni AA; Boutajangout A; Quartermain D; Sigurdsson EM
J Neurosci; 2007 Aug; 27(34):9115-29. PubMed ID: 17715348
[TBL] [Abstract][Full Text] [Related]
14. Tau passive immunization inhibits not only tau but also Aβ pathology.
Dai CL; Tung YC; Liu F; Gong CX; Iqbal K
Alzheimers Res Ther; 2017 Jan; 9(1):1. PubMed ID: 28073379
[TBL] [Abstract][Full Text] [Related]
15. Tau immunotherapy for Alzheimer's disease.
Pedersen JT; Sigurdsson EM
Trends Mol Med; 2015 Jun; 21(6):394-402. PubMed ID: 25846560
[TBL] [Abstract][Full Text] [Related]
16. Passive immunization with phospho-tau antibodies reduces tau pathology and functional deficits in two distinct mouse tauopathy models.
Sankaranarayanan S; Barten DM; Vana L; Devidze N; Yang L; Cadelina G; Hoque N; DeCarr L; Keenan S; Lin A; Cao Y; Snyder B; Zhang B; Nitla M; Hirschfeld G; Barrezueta N; Polson C; Wes P; Rangan VS; Cacace A; Albright CF; Meredith J; Trojanowski JQ; Lee VM; Brunden KR; Ahlijanian M
PLoS One; 2015; 10(5):e0125614. PubMed ID: 25933020
[TBL] [Abstract][Full Text] [Related]
17. Dynamic assessment of tau immunotherapies in the brains of live animals by two-photon imaging.
Wu Q; Lin Y; Gu J; Sigurdsson EM
EBioMedicine; 2018 Sep; 35():270-278. PubMed ID: 30146345
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy for Alzheimer's disease.
Wang W; Fan L; Xu D; Wen Z; Yu R; Ma Q
Acta Biochim Biophys Sin (Shanghai); 2012 Oct; 44(10):807-14. PubMed ID: 22899646
[TBL] [Abstract][Full Text] [Related]
19. Tau immunotherapies: Lessons learned, current status and future considerations.
Sandusky-Beltran LA; Sigurdsson EM
Neuropharmacology; 2020 Sep; 175():108104. PubMed ID: 32360477
[TBL] [Abstract][Full Text] [Related]
20. Passive immunization with anti-Tau antibodies in two transgenic models: reduction of Tau pathology and delay of disease progression.
Chai X; Wu S; Murray TK; Kinley R; Cella CV; Sims H; Buckner N; Hanmer J; Davies P; O'Neill MJ; Hutton ML; Citron M
J Biol Chem; 2011 Sep; 286(39):34457-67. PubMed ID: 21841002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
